Advances in Pancreatic Ductal Adenocarcinoma Treatment
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest malignancies among all cancers. Despite curative intent, surgery and the use of standard cytotoxic chemotherapy and radiation therapy, PDAC remains treatment-resistant. In recent years, more contemporary treatment modalities such as imm...
Guardado en:
Autores principales: | Eric M. Anderson, Shant Thomassian, Jun Gong, Andrew Hendifar, Arsen Osipov |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9301890896ec4394b03de377be109ce0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
por: Hong-Bo Li, et al.
Publicado: (2021) -
Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer
por: Courtney T. Stump, et al.
Publicado: (2021) -
Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance
por: Kostas Palamaris, et al.
Publicado: (2021) -
Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma
por: Iranzu González-Borja, et al.
Publicado: (2021) -
Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
por: Virginia Liberini, et al.
Publicado: (2021)